Intravitreal
bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Bevacizumab has been applied in the treatment of cerebral radiation necrosis.
To the Editor: An outbreak of endophthalmitis associated with repackaged
bevacizumab occurred during February-March 2013 in Georgia and Indiana, USA.
(NASDAQ: OTLK) (the 'Company'), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic
bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab (Lucentis) for wet AMD.
M2 PHARMA-August 16, 2019-Lynparza Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment with
Bevacizumab for Advanced Ovarian Cancer
M2 EQUITYBITES-August 15, 2019-AstraZeneca and MSD reveal phase three trial results for Lynparza in combination with
bevacizumabThe trial, in the first-line maintenance setting, compared LYNPARZA added to standard-of-care
bevacizumab versus
bevacizumab alone in women with or without BRCA-gene mutations.
Keywords: Avastin,
Bevacizumab, Branch retinal vein occlusion, Intravitreal injections, Vascular endothelial growth factor.
Global Banking News-January 29, 2019-Innovent Biologics Inc submits NDA for biosimilar product candidate of
bevacizumab with the NMPA for multiple types of malignant tumors
In this study, we compared the proliferative and cytotoxic effects of asbercept (0.5 mg/mL),
bevacizumab (0.3125 mg/mL), and ranibizumab (0.125 mg/mL) on RPE cell cultures by evaluating viability, apoptosis, proliferation, and senescence in control and drug-treated cells after 72 hours.